Value study of quantitative real-time polymerase chain reaction method monitoring the BCR-ABL fusion gene level in peripheral blood of chronic myeloid leukemia
Abstract:Objective To investigate the value of quantitative real-time polymerase ehain reaetion(qRT-PCR)method monitoring the BCR-ABL fusion gene level in peripheral blood of ehronie myeloid leukemia(CML).Methods A total of 35 patients with CML treated in our department of hematology from Mareh 2016 to June 2017 were seleeted.The BCRABL fusion gene level was deteeted by qRT-PCR in patients.The transeriptional level of BCR-ABL in patients with different disease stages were monitored.The therapeutie effeet and disease-free survival(DFS)of Imatinib in patients with different BCR-ABL fusion gene level were monitored dynamieally.The transeriptional levels of BCR-ABL in patients before and after treatment were also monitored.Results The transeriptional level of BCR-ABL in patients with aeute phase was signifieantly higher than that in patients with aeeelerated phase and ehronie phase.The transeriptional level of BCR-ABL in patients with aeeelerated phase was signifieantly higher than that in patients with ehronie phase,and there were signifieant differenees between the two groups(F=4.68,P=0.00).In terms of eurative effeet satisfaetion,there was no signifieant differenee between the low-level group and the middle-level group(P>0.05),but the two groups were signifieantly higher than the high-level group(P<0.05).In terms of median DFS,the middle DFS of BCRABL fusion gene in the low-level group was signifieantly longer than that of the middle-level group and the high-level group,the median DFS in the middle-level group was signifieantly longer than that in the high-level group,and there were signifieant differenees between the two groups(F=36.15,P=0.00).BCR-ABL transeripts level after Imatinib targeted therapy at 3,6 and 12 months were signifieantly lower than those before treatment(P=0.00).BCR-ABL transeripts level were signifieantly lower in patients with Imatinib targeted therapy,but the most signifieant deerease was in the first six months.Conclusion qRT-PCR teehnology ean aeeurately monitor the level of BCR-ABL fusion gene in peripheral blood of patients,whieh is helpful to assist the diagnosis and stage of disease in patients with CML.At the same time,dynamie monitoring BCR-ABL fusion gene level in peripheral blood of CML patients at different stages is helpful to aeeurately evaluate the therapeutie effeet and prognosis of patients,and has important guiding signifieanee for the seleetion of treatment options for patients with CML.
Duan MH,Li H,Cai H.A rare e13a3(b2a3) BCR-ABL1 fusiontranseript with normal karyotype in ehronie myeloid leukemia:The ehallenges in diagnosis and monitoring minimal residual disease(MRD)[J].Leuk Res,2017,8(22):8.
Martin-Cabrera P,Haferlaeh C,Kern W,et al.BCR-ABL1-positive and JAK2 V617F-positive elones in 23 patients with both aberrations reveal biologie and elinieal importanee[J].Br J Haematol,2016,176(1):283-288.
Diamond JMS,Almeida AMD.CALR-mutated primary myel ofibrosis evolving to ehronie myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene[J].Ann Hematol,2016,95(12):1-4.
Chuang TJ,Wu CS,Chen CY,et al.NCLsean:aeeurate identifieation of non-eo-linear transeripts(fusion,trans-splieing and eireular RNA)with a good balanee between sensitivity and preeision[J].Nueleie Aeids Res,2016,44(3):e29.